<span item_type="fundamental" item_id="66c68323d83bb58fe78c1852e505e3f0" counter_id="ST/US/CLYM" env="prod"></span><span item_type="announcement" item_id="548582502016946945" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.13.</p><p></p><h3>Cash Position</h3><ul><li>Cash, cash equivalents, and marketable securities were $187.4 million as of June 30, 2025. These funds are expected to support operations through 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-ex99_1.htm"></span></li></ul><h3>Research and Development (R&amp;D) Expenses</h3><ul><li>R&amp;D expenses were $6.6 million for the three months ended June 30, 2025, compared to $1.0 million for the same period in 2024, indicating a significant increase in R&amp;D investment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-ex99_1.htm"></span></li></ul><h3>Acquired In-Process Research and Development (IPR&amp;D) Expense</h3><ul><li>There were no IPR&amp;D expenses for the three months ended June 30, 2025, compared to $51.7 million in the same period in 2024, which was due to the acquisition of Tenet Medicines.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-ex99_1.htm"></span></li></ul><h3>General and Administrative (G&amp;A) Expenses</h3><ul><li>G&amp;A expenses were $4.1 million for the three months ended June 30, 2025, compared to $3.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-ex99_1.htm"></span></li></ul><h3>Other Income, Net</h3><ul><li>Other income, net was $2.0 million for the three months ended June 30, 2025, compared to $1.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-ex99_1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>The net loss was - $8.7 million for the three months ended June 30, 2025, compared to - $54.9 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Climb Bio anticipates initiating the Phase 2 trial for primary membranous nephropathy (pMN) and the Phase 1 trial for the subcutaneous formulation of budoprutug in the second half of 2025. Initial results for the subcutaneous formulation are expected in the first half of 2026. The company also plans to submit an IND or CTA for CLYM116 in IgA nephropathy in the second half of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-ex99_1.htm"></span></li></ul>

Climb Bio | 8-K: FY2025 Q2 EPS: USD -0.13